I suppose this is to be expected for a company without a retail product undergoing an expensive R & D process with its lead candidate.
Opexa Therapeutics 4Q Loss Widens
Opexa Therapeutics' 4th-Quarter Loss Widens on Higher Research and Development Costs
March 18, 2008: 09:22 AM EST
NEW YORK (Associated Press) - Biotechnology company Opexa Therapeutics Inc. said Tuesday its 2007 loss widened on higher research and development expenses.
The company lost $14.7 million, or ...